Overview
It is a prospective, multicenter, randomised controlled, open-label, blinded endpoint assessment trial, to compare the strategy of immediate complete revascularisation and staged complete revascularisation in ST-segment-elevation myocardial infarction patients with multivessel coronary disease.
Description
Objectives: The purpose of this study is to investigate whether FFR guided PCI strategy for non-culprit lesions should be attempted during the index procedure or staged in ST-segment-elevation myocardial infarction patients with multivessel coronary disease.
Inclusion Criteria:
- Age ≥ 18 years
- Patients presenting STEMI and multivessel coronary disease successful primary PCI of the culprit lesion (including those who still have ischemic symptoms within 48 hours)
- Multivessel disease was defined at least one non-culprit coronary arteries with a diameter of 2.5 mm or more and a maximum diameter at least 50% stenosis by visual estimation, PCI can be successfully implemented
- Sign an informed consent form before participating in the study
Exclusion Criteria:
- Received thrombolytic therapy
- Cardiac shock or SBP<90mmHg;
- History of old myocardial infarction;
- Left main artery lesion, non infarct related vessels are CTO lesions;
- PCI in the previous 30 days or Previous CABG
- Patients who cannot give informed consent or have a life expectancy of less than 1 year
- Patients combined with other serious diseases such as severe renal dysfunction (creatinine clearance value<30ml/min;), liver dysfunction and thrombocytopenia
- Patients with severe valve disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension;
- Not suitable for clinical research:
- . Currently participating in another study that may affect the primary endpoint
- . Pregnant and lactating women;
- . Known allergy to drugs that may be used in the study;
- . Unable to comply with the trial protocol or follow-up requirements; Or the researcher believes that participating in the trial may result in patients facing greater risks.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years
- Patients presenting STEMI and multivessel coronary disease successful primary PCI of the culprit lesion (including those who still have ischemic symptoms within 48 hours)
- Multivessel disease was defined at least one non-culprit coronary arteries with a diameter of 2.5 mm or more and a maximum diameter at least 50% stenosis by visual estimation, PCI can be successfully implemented
- Sign an informed consent form before participating in the study
Exclusion Criteria:
- Received thrombolytic therapy
- Cardiac shock or SBP<90mmHg;
- History of old myocardial infarction;
- Left main artery lesion, non infarct related vessels are CTO lesions;
- PCI in the previous 30 days or Previous CABG
- Patients who cannot give informed consent or have a life expectancy of less than 1 year
- Patients combined with other serious diseases such as severe renal dysfunction (creatinine clearance value<30ml/min;), liver dysfunction and thrombocytopenia
- Patients with severe valve disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension;
- Not suitable for clinical research:
- Currently participating in another study that may affect the primary endpoint
- Pregnant and lactating women;
- Known allergy to drugs that may be used in the study;
- Unable to comply with the trial protocol or follow-up requirements; Or the researcher believes that participating in the trial may result in patients facing greater risks.